Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany.
Saved in:
| Title: | Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany. |
|---|---|
| Authors: | Winter, Y., Balzer-Geldsetzer, M., Spottke, A., Reese, J. P., Baum, E., Klotsche, J., Rieke, J., Simonow, A., Eggert, K., Oertel, W. H., Dodel, Richard |
| Source: | European Journal of Neurology. Sep2010, Vol. 17 Issue 9, p1156-1163. 8p. 5 Charts, 1 Graph. |
| Subjects: | Medical economics, Parkinson's disease, Regression analysis, Medical care |
| Geographic Terms: | Germany |
| Abstract: | Objective: To determine the health economic burden on patients with Parkinson’s disease (PD) in Germany over a 12-month observation period and provide a comprehensive analysis of cost-driving factors. Methods and patients: Patients with PD ( n = 145) were recruited from two clinical departments, two office-based neurologists and 12 GPs. Clinical evaluations were performed at baseline, 3, 6 and 12 months. Disease severity was measured using the Unified Parkinson’s Disease Rating Scale (UPDRS). Cost data were assessed based on a patient diary and via personal structured interviews at the respective time-points. Costs were calculated from the societal perspective (2009 €). Cost-driving factors were identified by multivariate regression analysis. Results: Mean annual costs totalled €20 095 per patient. Amongst direct costs, the highest expenditures (€13 158) were for drugs (€3526) and inpatient care including nursing homes (€3789). Indirect costs accounted for 34.5% (€6937) of total costs. Costs of home care provided by family accounted for 20% of direct costs. Cost-driving factors were identified for total costs (UPDRS, fluctuations, dyskinesia and younger age), direct costs (UPDRS, fluctuations), patient expenditures (UPDRS, depression) and drug costs (younger age). Conclusion: Parkinson’s disease has a chronic course with growing disability and considerable socioeconomic burden. Disease progression leads to an increasing number of patients who require costly institutionalized care. Home care is a major factor influencing patients’ families. Healthcare programmes aimed at reducing the burden of PD on society and individuals should consider cost-driving factors of PD. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
Be the first to leave a comment!
